Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes

Virus Research

Volumn 175, Issue 2, 2013, Pages 155-159

  Woodson, Sara E ^a,b   Freiberg, Alexander N ^a   Holbrook, Michael R ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

17 D vaccine; Asibi virus; Fibrinogen; Hepatocytes; Plasminogen activator inhibitor 1; Yellow fever virus

Indexed keywords

FIBRINOGEN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; YELLOW FEVER VACCINE;

ARTICLE; BLEEDING; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; VACCINATION; VIRUS STRAIN; YELLOW FEVER FLAVIVIRUS;

CELL LINE; FIBRINOGEN; GENE EXPRESSION; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC; YELLOW FEVER VIRUS;

FLAVIVIRUS; YELLOW FEVER VIRUS;

EID: 84878824672     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.04.013     Document Type: Article

References (41)

1. Albrecht U., Yang X., Asselta R., Keitel V., Tenchini M.L., Ludwig S., Heinrich P.C., Haussinger D., Schaper F., Bode J.G. Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cellular Signalling 2007, 19(9):1866-1878.
2. Barrett A.D., Higgs S. Yellow fever: a disease that has yet to be conquered. Annual Review of Entomology 2007, 52:209-229.
3. Ceciliani F., Giordano A., Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein and Peptide Letters 2002, 9(3):211-223.
4. Colebunders R., Mariage J.L., Coche J.C., Pirenne B., Kempinaire S., Hantson P., Van Gompel A., Niedrig M., Van Esbroeck M., Bailey R., Drosten C., Schmitz H. A Belgian traveler who acquired yellow fever in the Gambia. Clinical Infectious Diseases 2002, 35(10):e113-e116.
5. Djamiatun K., Faradz S.M., Setiati T.E., Netea M.G., van der Ven A.J., Dolmans W.M. Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-b1 in children with dengue haemorrhagic fever in Indonesia. Journal of Tropical Pediatrics 2000, 57(6):424-432.
6. Elton N., Romero A., Trejos A. Clinical pathology of yellow fever. American Journal of Clinical Pathology 1955, 25(2):135-146.
7. Gabay C., Gigley J., Sipe J., Arend W.P., Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. European Journal of Immunology 2001, 31(2):490-499.
8. Guillen M.I., Gomez-Lechon M.J., Nakamura T., Castell J.V. The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Hepatology 1996, 23(6):1345-1352.
9. Hahn C.S., Dalrymple J.M., Strauss J.H., Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proceedings of the National Academy of Sciences of the United States of America 1987, 84(7):2019-2023.
10. Huang Y.H., Liu C.C., Wang S.T., Lei H.Y., Liu H.L., Lin Y.S., Wu H.L., Yeh T.M. Activation of coagulation and fibrinolysis during dengue virus infection. Journal of Medical Virology 2001, 63(3):247-251.
11. Iacoviello L., Vischetti M., Zito F., Benedetta Donati M. Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001, 38(5):1199-1203.
12. Jankun J., Skrzypczak-Jankun E. Yin and yang of the plasminogen activator inhibitor. Polskie Archiwum Medycyny Wewnetrznej 2009, 119(6):410-417.
13. Jiang Z., Tang X., Xiao R., Jiang L., Chen X. Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells. Journal of Infection 2007, 55(2):e23-e28.
14. Johnson A., Ritchie R., Ledue T. Protein Learning Guide 2004, 1-37. Abbott Diagnostics, Inc.
15. Klotz O., Belt T. Pathology of the liver in yellow fever. The American Journal of Pathology 1930, 6(6):663-688.
16. Kooistra T., Bosma P.J., Tons H.A., van den Berg A.P., Meyer P., Princen H.M. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thrombosis and Haemostasis 1989, 62(2):723-728.
17. Kornelisse R.F., Hazelzet J.A., Savelkoul H.F., Hop W.C., Suur M.H., Borsboom A.N., Risseeuw-Appel I.M., van der Voort E., de Groot R. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. Journal of Infectious Diseases 1996, 173(5):1148-1156.
18. Lloyd W. The myocardium in yellow fever II. The myocardial lesions in experimental yellow fever. American Heart Journal 1931, 6:504-516.
19. Marchi R., Nagaswami C., Weisel J.W. Fibrin formation and lysis studies in dengue virus infection. Blood Coagulation and Fibrinolysis 2009, 20(7):575-582.
20. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., Shieh W., Zaki S.R., Al-Sanouri I., Cutrona A.F., Ray G., Weld L.H., Cetron M.S. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
21. Mazuski J.E., Tolman K., Shapiro M.J. Effects of cytokine antagonists on the hepatic acute-phase response. Journal of Surgical Research 1997, 68(2):161-169.
22. McFarland J.M., Baddour L.M., Nelson J.E., Elkins S.K., Craven R.B., Cropp B.C., Chang G.J., Grindstaff A.D., Craig A.S., Smith R.J. Imported yellow fever in a United States citizen. Clinical Infectious Diseases 1997, 25(5):1143-1147.
23. McGavran M.H., White J.D. Electron microscopic and immunofluorescent observations on monkey liver and tissue culture cells infected with the Asibi strain of yellow fever virus. American Journal of Pathology 1964, 45:501-517.
24. Migita K., Abiru S., Nakamura M., Komori A., Yoshida Y., Yokoyama T., Daikoku M., Ueki T., Takii Y., Yano K., Yastuhashi H., Eguchi K., Ishibashi H. Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Letters 2004, 569(1-3):235-239.
25. Monath T.P., Barrett A.D. Pathogenesis and pathophysiology of yellow fever. Advances in Virus Research 2003, 60:343-395.
26. Monath T.P., Craven R.B., Adjukiewicz A., Germain M., Francy D.B., Ferrara L., Samba E.M., N'Jie H., Cham K., Fitzgerald S.A., Crippen P.H., Simpson D.I., Bowen E.T., Fabiyi A., Salaun J.J. Yellow fever in the Gambia, 1978-1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. American Journal of Tropical Medicine and Hygiene 1980, 29(5):912-928.
27. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., Marchesani R., Knauber M., Wells K.H., Arroyo J., Guirakhoo F. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002, 20(7-8):1004-1018.
28. Nasidi A., Monath T.P., DeCock K., Tomori O., Cordellier R., Olaleye O.D., Harry T.O., Adeniyi J.A., Sorungbe A.O., Ajose-Coker A.O., et al. Urban yellow fever epidemic in western Nigeria, 1987. Transactions of the Royal Society of Tropical Medicine and Hygiene 1989, 83(3):401-406.
29. Oppenheim J., Feldmann M. Cytokine Reference, Ligands 2001, 534-537. Academic Press, London, UK/San Diego, CA.
30. Raynes J.G., Bevan S. Inhibition of the acute-phase response in a human hepatoma cell line. Agents Actions 1993, 38. Spec No. C66-68.
31. Rice C.M., Grakoui A., Galler R., Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biologist 1989, 1(3):285-296.
32. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229(4715):726-733.
33. Schultz D.R., Arnold P.I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Seminars in Arthritis and Rheumatism 1990, 20(3):129-147.
34. Thibodeaux B.A., Garbino N.C., Liss N.M., Piper J., Blair C.D., Roehrig J.T. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 2012, 30(21):3180-3187.
35. van der Beek M.T., Visser L.G., de Maat M.P. Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascular Pharmacology 2002, 39(3):117-121.
36. Van Gorp E.C., Setiati T.E., Mairuhu A.T., Suharti C., Cate Ht H., Dolmans W.M., Van Der Meer J.W., Hack C.E., Brandjes D.P. Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. Journal of Medical Virology 2002, 67(4):549-554.
37. Vasse M., Paysant J., Soria J., Collet J.P., Vannier J.P., Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis 1996, 26(Suppl. 4):331-339.
38. Verschuur M., van der Beek M.T., Tak H.S., Visser L.G., de Maat M.P. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagulation and Fibrinolysis 2004, 15(5):399-404.
39. Wheelock E.F., Sibley W.A. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. New England Journal of Medicine 1965, 273:194-198.
40. Woodson S.E., Freiberg A., Holbrook M.R. Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 2011, 412:188-195.
41. Woodson S.E., Holbrook M.R. Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. Journal of General Virology 2011, 92(Pt. 10):2262-2271.